Gastrointestinal Cancer News

The FDA has issued the following approvals for oncology indications:

The Metropolitan Chicago Breast Cancer Task Force held an evening art gallery event for its survivors in October. For the task force, it was a celebration of successful efforts in navigating underserved, minority patients with cancer toward quality care.

The trends are clear — not only do ethnic and racial minority groups face poorer cancer outcomes, they also are less frequently invited to participate in clinical trials, more often experience delays in treatment and initiation of palliative care, and are less likely to be offered genetic testing.

Psychosocial risk factors considerably increased risk for complications among patients with medical comorbidities who underwent cancer surgery, according to study results published in Annals of Surgical Oncology.

Comprehensive molecular profiling feasibly identified potentially actionable mutations among children and adolescents with hard-to-treat cancers, according to results of a prospective study published in JAMA Network Open.

The CDC plans to launch a new registry that could help researchers better understand occupational cancer risk among firefighters.

The University of Illinois Cancer Center has received a 3-year, $1.5 million grant from the Bristol-Myers Squibb Foundation to support programs intended to reduce cancer disparities in the Chicago area, according to a press release.

Visceral fat and muscle radiodensity appeared significantly associated with risk for major adverse cardiovascular events among patients with colorectal cancer, according to study results published in JAMA Oncology.

Current smokers are less likely to meet recommendations for breast, prostate and colorectal cancer screenings than people who have never smoked, according to results from a recent study published in JAMA Network Open.

A lower-dose, less-toxic regimen of oxaliplatin and capecitabine conferred comparable PFS as the higher-dose regimen among frail and/or elderly patients with advanced gastroesophageal cancer, according to results from the randomized phase 3 GO2 trial scheduled for presentation at ASCO Annual Meeting.